Following promising pre-clinical trials at the University of Southampton, Biolnvents B1-1206 (a new fully-human antibody) is to enter a collaborative phase I/II for patients with chronic lymphocytic leukaemia and non Hodgkin lymphoma.
Copy and paste this URL into your WordPress site to embed
